The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells

Oncotarget

Volumn 6, Issue 33, 2015, Pages 34910-34923

  Eike, Liv Marie ^a   Yang, Nannan ^a   Rekdal, Oystein ^a,b   Sveinbjornsson, Baldur ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b LYTIX BIOPHARMA AS   (Norway)

Author keywords

DAMPs; Melanoma; Oncolytic peptide

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYTOCHROME C; HIGH MOBILITY GROUP B1 PROTEIN; PEPTIDE DERIVATIVE; PEPTIDE LTX 315; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; LACTOFERRICIN B; LACTOFERRIN; PEPTIDE;

A375 CELL LINE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL MEMBRANE; CELL STRUCTURE; CELL VACUOLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOLYSIS; DEPOLARIZATION; DRUG CYTOTOXICITY; FLUORESCENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; MELANOMA CELL; MEMBRANE DAMAGE; MITOCHONDRIAL MEMBRANE POTENTIAL; SUPERNATANT; TRANSMISSION ELECTRON MICROSCOPY; CELL DEATH; CHEMISTRY; DRUG EFFECTS; MELANOMA; MITOCHONDRION; PATHOLOGY; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CELL MEMBRANE; HUMANS; LACTOFERRIN; MELANOMA; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, TRANSMISSION; MITOCHONDRIA; PEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84946568247     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5308     Document Type: Article

References (74)

1. Zasloff, M., Antimicrobial peptides of multicellular organisms. Nature, 2002. 415: p. 389-95.
2. Hoskin, D.W. and A. Ramamoorthy, Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta,2008. 1778: p. 357-75.
3. Mader, J.S. and D.W. Hoskin, Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin Investig Drugs, 2006. 15: p. 933-46.
4. Yasin, B., M. Pang, J.S. Turner, Y. Cho, N.N. Dinh, A.J. Waring, R.I. Lehrer, and E.A. Wagar, Evaluation of the inactivation of infectious Herpes simplex virus by hostdefense peptides. Eur J Clin Microbiol Infect Dis, 2000. 19: p. 187-94.
5. Rosenfeld, Y. and Y. Shai, Lipopolysaccharide (Endotoxin)-host defense antibacterial peptides interactions: role in bacterial resistance and prevention of sepsis. Biochim Biophys Acta, 2006. 1758: p. 1513-22.
6. Yang, D., A. Biragyn, D.M. Hoover, J. Lubkowski, and J.J. Oppenheim, Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu Rev Immunol, 2004. 22: p. 181-215.
7. Eliassen, L.T., G. Berge, A. Leknessund, M. Wikman, I. Lindin, C. Lokke, F. Ponthan, J.I. Johnsen, B. Sveinbjornsson, P. Kogner, T. Flaegstad, and O. Rekdal, The antimicrobial peptide, lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo. Int J Cancer, 2006. 119: p. 493-500.
8. Eliassen, L.T., G. Berge, B. Sveinbjornsson, J.S. Svendsen, L.H. Vorland, and O. Rekdal, Evidence for a direct antitumor mechanism of action of bovine lactoferricin. Anticancer Res, 2002. 22: p. 2703-10.
9. Furlong, S.J., J.S. Mader, and D.W. Hoskin, Bovine lactoferricin induces caspase-independent apoptosis in human B-lymphoma cells and extends the survival of immune-deficient mice bearing B-lymphoma xenografts. Exp Mol Pathol, 2010. 88: p. 371-5.
10. Yang, N., W. Stensen, J.S. Svendsen, and O. Rekdal, Enhanced antitumor activity and selectivity of lactoferrinderived peptides. J Pept Res, 2002. 60: p. 187-97.
11. Yang, N., T. Lejon, and O. Rekdal, Antitumour activity and specificity as a function of substitutions in the lipophilic sector of helical lactoferrin-derived peptide. J Pept Sci,2003. 9: p. 300-11.
12. Yang, N., M.B. Strom, S.M. Mekonnen, J.S. Svendsen, and O. Rekdal, The effects of shortening lactoferrin derived peptides against tumour cells, bacteria and normal human cells. J Pept Sci, 2004. 10: p. 37-46.
13. Berge, G., L.T. Eliassen, K.A. Camilio, K. Bartnes, B. Sveinbjornsson, and O. Rekdal, Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide. Cancer Immunol Immunother,2010. 59: p. 1285-94.
14. Camilio, K.A., O. Rekdal, and B. Sveinbjornsson, LTX-315 (Oncopore): A short synthetic anticancer peptide and novel immunotherapeutic agent. Oncoimmunology, 2014. 3: p. e29181.
15. Camilio, K.A., G. Berge, C.S. Ravuri, O. Rekdal, and B. Sveinbjornsson, Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315. Cancer Immunol Immunother,2014. 63: p. 601-13.
16. Yoo, Y.C., S. Watanabe, R. Watanabe, K. Hata, K. Shimazaki, and I. Azuma, Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn J Cancer Res, 1997. 88: p. 184-90.
17. Eliassen, L.T., B.E. Haug, G. Berge, and O. Rekdal, Enhanced antitumour activity of 15-residue bovine lactoferricin derivatives containing bulky aromatic amino acids and lipophilic N-terminal modifications. J Pept Sci, 2003. 9: p. 510-7.
18. Lotze, M.T. and K.J. Tracey, High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol, 2005. 5: p. 331-42.
19. Garg, A.D., D.V. Krysko, P. Vandenabeele, and P. Agostinis, The emergence of phox-ER stress induced immunogenic apoptosis. Oncoimmunology, 2012. 1: p. 786-788.
20. Sun, C., H. Wang, S. Mao, J. Liu, S. Li, and J. Wang, Reactive oxygen species involved in CT26 immunogenic cell death induced by Clostridium difficile toxin B. Immunol Lett, 2015. 164: p. 65-71.
21. Brookes, P.S., Y. Yoon, J.L. Robotham, M.W. Anders, and S.S. Sheu, Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J Physiol Cell Physiol, 2004. 287: p. C817-33.
22. Lopez-Armada, M.J., R.R. Riveiro-Naveira, C. VaamondeGarcia, and M.N. Valcarcel-Ares, Mitochondrial dysfunction and the inflammatory response. Mitochondrion, 2013. 13: p. 106-18.
23. Green, D.R., T. Ferguson, L. Zitvogel, and G. Kroemer, Immunogenic and tolerogenic cell death. Nat Rev Immunol,2009. 9: p. 353-63.
24. Eggermont, A.M., G. Kroemer, and L. Zitvogel, Immunotherapy and the concept of a clinical cure. Eur J Cancer, 2013. 49: p. 2965-7.
25. Buchbinder, E.I. and D.F. McDermott, Cytotoxic T-Lymphocyte Antigen-4 Blockade in Melanoma. Clin Ther, 2015. 37: p. 755-763.
26. Homet Moreno, B., G. Parisi, L. Robert, and A. Ribas, Anti-PD-1 Therapy in Melanoma. Semin Oncol, 2015. 42: p. 466-473.
27. Sharma, P. and J.P. Allison, The future of immune checkpoint therapy. Science, 2015. 348: p. 56-61.
28. Postow, M.A., M.K. Callahan, and J.D. Wolchok, Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol, 2015;33:1974-82.
29. Shin, D.S. and A. Ribas, The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol, 2015. 33: p. 23-35.
30. Aris, M. and M.M. Barrio, Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol, 2015. 6: p. 46.
31. Immunotherapy: combine and conquer. Nat Med. 2015; 21:415.
32. Epand, R.M. and H.J. Vogel, Diversity of antimicrobial peptides and their mechanisms of action. Biochim Biophys Acta, 1999. 1462: p. 11-28.
33. Fjell, C.D., J.A. Hiss, R.E. Hancock, and G. Schneider, Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov, 2012. 11: p. 37-51.
34. Riedl, S., D. Zweytick, and K. Lohner, Membrane-active host defense peptides-challenges and perspectives for the development of novel anticancer drugs. Chem Phys Lipids,2011. 164: p. 766-81.
35. Maletzki, C., U. Klier, S. Marinkovic, E. Klar, J. Andra, and M. Linnebacher, Host defense peptides for treatment of colorectal carcinoma-a comparative in vitro and in vivo analysis. Oncotarget, 2014. 5: p. 4467-79.
36. Al-Benna, S., Y. Shai, F. Jacobsen, and L. Steinstraesser, Oncolytic activities of host defense peptides. Int J Mol Sci,2011. 12: p. 8027-51.
37. Dobrzynska, I., B. Szachowicz-Petelska, S. Sulkowski, and Z. Figaszewski, Changes in electric charge and phospholipids composition in human colorectal cancer cells. Mol Cell Biochem, 2005. 276: p. 113-9.
38. Utsugi, T., A.J. Schroit, J. Connor, C.D. Bucana, and I.J. Fidler, Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res,1991. 51: p. 3062-6.
39. Riedl, S., B. Rinner, M. Asslaber, H. Schaider, S. Walzer, A. Novak, K. Lohner, and D. Zweytick, In search of a novel target-phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy. Biochim Biophys Acta, 2011. 1808: p. 2638-45.
40. Fadnes, B., L. Uhlin-Hansen, I. Lindin, and O. Rekdal, Small lytic peptides escape the inhibitory effect of heparan sulfate on the surface of cancer cells. BMC Cancer, 2011. 11: p. 116.
41. Nakatsura, T., T. Kageshita, S. Ito, K. Wakamatsu, M. Monji, Y. Ikuta, S. Senju, T. Ono, and Y. Nishimura, Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res, 2004. 10: p. 6612-21.
42. Kleeff, J., T. Ishiwata, A. Kumbasar, H. Friess, M.W. Buchler, A.D. Lander, and M. Korc, The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest, 1998. 102: p. 1662-73.
43. Kim, Y.J. and A. Varki, Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J, 1997. 14: p. 569-76.
44. Kufe, D.W., Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer, 2009. 9: p. 874-85.
45. Paszek, M.J., C.C. DuFort, O. Rossier, R. Bainer, J.K. Mouw, K. Godula, J.E. Hudak, J.N. Lakins, A.C. Wijekoon, L. Cassereau, M.G. Rubashkin, M.J. Magbanua, K.S. Thorn, et al., The cancer glycocalyx mechanically primes integrin-mediated growth and survival. Nature, 2014. 511: p. 319-25.
46. Lens, M.B. and T.G. Eisen, Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin Pharmacother, 2003. 4: p. 2205-11.
47. Britten, C.D., E.K. Rowinsky, S.D. Baker, S.S. Agarwala, J.R. Eckardt, R. Barrington, S.G. Diab, L.A. Hammond, T. Johnson, M. Villalona-Calero, U. Fraass, P. Statkevich, D.D. Von Hoff, et al., A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res, 1999. 5: p. 1629-37.
48. Schweizer, F., Cationic amphiphilic peptides with cancerselective toxicity. Eur J Pharmacol, 2009. 625: p. 190-4.
49. Mader, J.S., J. Salsman, D.M. Conrad, and D.W. Hoskin, Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. Mol Cancer Ther, 2005. 4: p. 612-24.
50. Holmstrom, K.M. and T. Finkel, Cellular mechanisms and physiological consequences of redox-dependent signalling. Nat Rev Mol Cell Biol, 2014. 15: p. 411-421.
51. Kong, Q., J.A. Beel, and K.O. Lillehei, A threshold concept for cancer therapy. Med Hypotheses, 2000. 55: p. 29-35.
52. Gupta, S.C., D. Hevia, S. Patchva, B. Park, W. Koh, and B.B. Aggarwal, Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal, 2012. 16: p. 1295-322.
53. Ryter, S.W. and A.M. Choi, Regulation of autophagy in oxygen-dependent cellular stress. Curr Pharm Des, 2013. 19: p. 2747-56.
54. Matzinger, P., Tolerance, danger, and the extended family. Annu Rev Immunol, 1994. 12: p. 991-1045.
55. Aymeric, L., L. Apetoh, F. Ghiringhelli, A. Tesniere, I. Martins, G. Kroemer, M.J. Smyth, and L. Zitvogel, Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res, 2010. 70: p. 855-8.
56. Krysko, D.V., A.D. Garg, A. Kaczmarek, O. Krysko, P. Agostinis, and P. Vandenabeele, Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer, 2012. 12: p. 860-75.
57. Martins, I., A. Tesniere, O. Kepp, M. Michaud, F. Schlemmer, L. Senovilla, C. Seror, D. Metivier, J.L. Perfettini, L. Zitvogel, and G. Kroemer, Chemotherapy induces ATP release from tumor cells. Cell Cycle, 2009. 8: p. 3723-8.
58. Wang, Y., I. Martins, Y. Ma, O. Kepp, L. Galluzzi, and G. Kroemer, Autophagy-dependent ATP release from dying cells via lysosomal exocytosis. Autophagy, 2013. 9.
59. Ma, Y., S. Adjemian, H. Yang, J.P. Catani, D. Hannani, I. Martins, M. Michaud, O. Kepp, A.Q. Sukkurwala, E. Vacchelli, L. Galluzzi, L. Zitvogel, and G. Kroemer, ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. Oncoimmunology, 2013. 2: p. e24568.
60. Krysko, D.V., P. Agostinis, O. Krysko, A.D. Garg, C. Bachert, B.N. Lambrecht, and P. Vandenabeele, Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol, 2011. 32: p. 157-64.
61. Tschopp, J., Mitochondria: Sovereign of inflammation? Eur J Immunol, 2011. 41: p. 1196-202.
62. Garg, A.D., S. Martin, J. Golab, and P. Agostinis, Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ, 2014. 21: p. 26-38.
63. Wenceslau, C.F., C.G. McCarthy, T. Szasz, K. Spitler, S. Goulopoulou, and R.C. Webb, Mitochondrial damage-associated molecular patterns and vascular function. Eur Heart J, 2014. 35: p. 1172-7.
64. Galluzzi, L., O. Kepp, C. Trojel-Hansen, and G. Kroemer, Mitochondrial control of cellular life, stress, and death. Circ Res, 2012. 111: p. 1198-207.
65. Ungvari, Z., Z. Orosz, N. Labinskyy, A. Rivera, Z. Xiangmin, K. Smith, and A. Csiszar, Increased mitochondrial H2O2 production promotes endothelial NF-kappaB activation in aged rat arteries. Am J Physiol Heart Circ Physiol, 2007. 293: p. H37-47.
66. Vaamonde-Garcia, C., R.R. Riveiro-Naveira, M.N. Valcarcel-Ares, L. Hermida-Carballo, F.J. Blanco, and M.J. Lopez-Armada, Mitochondrial dysfunction increases inflammatory responsiveness to cytokines in normal human chondrocytes. Arthritis Rheum, 2012. 64: p. 2927-36.
67. Pullerits, R., M. Bokarewa, I.M. Jonsson, M. Verdrengh, and A. Tarkowski, Extracellular cytochrome c, a mitochondrial apoptosis-related protein, induces arthritis. Rheumatology (Oxford), 2005. 44: p. 32-9.
68. Inoue, H. and K. Tani, Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ, 2014;21:39-49.
69. Volonte, C., S. Apolloni, S.D. Skaper, and G. Burnstock, P2X7 receptors: channels, pores and more. CNS Neurol Disord Drug Targets, 2012. 11: p. 705-21.
70. Alexiou, P., M. Chatzopoulou, K. Pegklidou, and V.J. Demopoulos, RAGE: a multi-ligand receptor unveiling novel insights in health and disease. Curr Med Chem, 2010. 17: p. 2232-52.
71. Kepp, O., A. Tesniere, F. Schlemmer, M. Michaud, L. Senovilla, L. Zitvogel, and G. Kroemer, Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis, 2009. 14: p. 364-75.
72. Ladoire, S., D. Hannani, M. Vetizou, C. Locher, L. Aymeric, L. Apetoh, O. Kepp, G. Kroemer, F. Ghiringhelli, and L. Zitvogel, Cell-death-associated molecular patterns as determinants of cancer immunogenicity. Antioxid Redox Signal, 2014. 20: p. 1098-116.
73. Zitvogel, L., A. Tesniere, L. Apetoh, F. Ghiringhelli, and G. Kroemer, [Immunological aspects of anticancer chemotherapy]. Bull Acad Natl Med, 2008. 192: p. 1469-87; discussion 1487-9.
74. Matzinger, P., The danger model: a renewed sense of self. Science, 2002. 296: p. 301-5.